View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAltitude Acquisition 過去の業績過去 基準チェック /06Altitude Acquisition は平均年間 2.3% の収益成長を遂げていますが、Capital Markets 業界では年間 収益成長率 となっています。5.8% です。主要情報2.27%収益成長率-206.07%EPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Sep 2023最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 24Altitude Acquisition Corp. Files Form 15Altitude Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, Class A common stock, par value $0.0001, Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an excise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.お知らせ • Mar 14+ 1 more updateAltitude Acquisition Corp.(NasdaqCM:ALTU) dropped from NASDAQ Composite IndexAltitude Acquisition Corp. has been removed from NASDAQ Composite Index .お知らせ • Nov 15Altitude Acquisition Corp. announced delayed 10-Q filingOn 11/14/2023, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Founder, President, CEO & Director Gary Teplis is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 05Altitude Acquisition in Talks to Merge with Medical Device ManufacturerAltitude Acquisition Corp. (NasdaqCM:ALTU), a publicly traded special purpose acquisition company, said it has entered into negotiations to merge with a "leading global medical device manufacturer in a deal that pegs the enterprise value of the company at approximately $480 million." The proposed transaction calls for the combined company to have at least $20 million in net cash at time of closing. The target seeks additional expansion in the U.S., globally and in new jurisdictions around the world, Altitude said in a statement. Altitude anticipates entering into a letter of intent on or around October 31 and a definitive merger agreement as soon as practicable thereafter. "We believe the target is a market leader in its field and a business combination would represent a tremendous opportunity for us and our shareholders," said Gary Teplis, Chief Executive Officer of Altitude. "I would also like to remind our stockholders that Altitude is seeking stockholder approval of an extension of time to complete our initial business combination, from October 11, 2022, to April 11, 2023 (the "Extension")".お知らせ • Sep 14Altitude Acquisition Corp. Announces Executive ChangesOn September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. of his decision to resign from his position as Chairman of the board of directors of the Company and from the audit committee of the Board effective immediately.On September 9, 2022, Thomas Breitling notified the Company of his decision to resign from his position as Vice Chairman of the Board and from the compensation committee of the Board effective immediately. In connection with the resignations of Mr. Isaacs and Mr. Breitling, on September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a Class III director on the Board, Chairman of the Board, and as a member of the Audit Committee and Compensation Committee, effective immediately. Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings Inc., has been a member of its board of directors since July 2008, and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings Inc. from March 2021 to March 2022, and following a business combination with Nutex Health Inc. he continues to be a director and President of Nutex Health Inc. from March 2022 to present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences, his medical degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center.お知らせ • Aug 23Altitude Acquisition Corp. Announces Resignation of Kevin Schubert as Chief Operating Officer, Effective August 18, 2022On August 18, 2022, Kevin Schubert notified Altitude Acquisition Corp. of his decision to resign from his position as Chief Operating Officer, effective August 18, 2022. Mr. Schubert’s decision to resign is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.お知らせ • Aug 17Altitude Acquisition Corp. announced delayed 10-Q filingOn 08/16/2022, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 26Getaround Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionGetaround is in talks to go public through a merger with special purpose acquisition company (SPAC) Altitude Acquisition Corp. (NasdaqCM:ALTU), people familiar with the matter said. The company has confidentially sought investors to participate in the deal through a private placement in public equity, or PIPE, at a valuation of around $1.7 billion, one of the sources said. The sources cautioned that terms could change and said there was no certainty of a deal. They asked not to be identified because the negotiations are not public. Altitude Acquisition Corp. declined to comment. Getaround did not immediately respond to requests for comment.お知らせ • May 18Altitude Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 19Aerion Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionAerion Corporation is in talks to go public through a merger with Altitude Acquisition Corp. (NasdaqCM:ALTU), according to people with knowledge of the matter. The companies are discussing a deal that would value the combined firm at up to $3 billion, said the people, who asked to not be identified because the matter isn’t public. A deal could be announced as soon as in February 2021, the people said. The talks could still fall apart and end without an agreement, they said. A spokesperson for Aerion declined to comment. A representative for Altitude Acquisition didn’t immediately respond to a request for comment.収支内訳Altitude Acquisition の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:ALTU 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 230-45030 Jun 230-24031 Mar 230-14031 Dec 22093030 Sep 220133030 Jun 220118031 Mar 220306031 Dec 2101560質の高い収益: ALTUは現在利益が出ていません。利益率の向上: ALTUは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ALTUの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: ALTUの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ALTUは利益が出ていないため、過去 1 年間の収益成長をCapital Markets業界 ( 35.9% ) と比較することは困難です。株主資本利益率高いROE: ALTUの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/03/13 13:00終値2024/03/13 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Altitude Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 24Altitude Acquisition Corp. Files Form 15Altitude Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, Class A common stock, par value $0.0001, Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an excise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.
お知らせ • Mar 14+ 1 more updateAltitude Acquisition Corp.(NasdaqCM:ALTU) dropped from NASDAQ Composite IndexAltitude Acquisition Corp. has been removed from NASDAQ Composite Index .
お知らせ • Nov 15Altitude Acquisition Corp. announced delayed 10-Q filingOn 11/14/2023, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Founder, President, CEO & Director Gary Teplis is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 05Altitude Acquisition in Talks to Merge with Medical Device ManufacturerAltitude Acquisition Corp. (NasdaqCM:ALTU), a publicly traded special purpose acquisition company, said it has entered into negotiations to merge with a "leading global medical device manufacturer in a deal that pegs the enterprise value of the company at approximately $480 million." The proposed transaction calls for the combined company to have at least $20 million in net cash at time of closing. The target seeks additional expansion in the U.S., globally and in new jurisdictions around the world, Altitude said in a statement. Altitude anticipates entering into a letter of intent on or around October 31 and a definitive merger agreement as soon as practicable thereafter. "We believe the target is a market leader in its field and a business combination would represent a tremendous opportunity for us and our shareholders," said Gary Teplis, Chief Executive Officer of Altitude. "I would also like to remind our stockholders that Altitude is seeking stockholder approval of an extension of time to complete our initial business combination, from October 11, 2022, to April 11, 2023 (the "Extension")".
お知らせ • Sep 14Altitude Acquisition Corp. Announces Executive ChangesOn September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. of his decision to resign from his position as Chairman of the board of directors of the Company and from the audit committee of the Board effective immediately.On September 9, 2022, Thomas Breitling notified the Company of his decision to resign from his position as Vice Chairman of the Board and from the compensation committee of the Board effective immediately. In connection with the resignations of Mr. Isaacs and Mr. Breitling, on September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a Class III director on the Board, Chairman of the Board, and as a member of the Audit Committee and Compensation Committee, effective immediately. Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings Inc., has been a member of its board of directors since July 2008, and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings Inc. from March 2021 to March 2022, and following a business combination with Nutex Health Inc. he continues to be a director and President of Nutex Health Inc. from March 2022 to present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences, his medical degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center.
お知らせ • Aug 23Altitude Acquisition Corp. Announces Resignation of Kevin Schubert as Chief Operating Officer, Effective August 18, 2022On August 18, 2022, Kevin Schubert notified Altitude Acquisition Corp. of his decision to resign from his position as Chief Operating Officer, effective August 18, 2022. Mr. Schubert’s decision to resign is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
お知らせ • Aug 17Altitude Acquisition Corp. announced delayed 10-Q filingOn 08/16/2022, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 26Getaround Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionGetaround is in talks to go public through a merger with special purpose acquisition company (SPAC) Altitude Acquisition Corp. (NasdaqCM:ALTU), people familiar with the matter said. The company has confidentially sought investors to participate in the deal through a private placement in public equity, or PIPE, at a valuation of around $1.7 billion, one of the sources said. The sources cautioned that terms could change and said there was no certainty of a deal. They asked not to be identified because the negotiations are not public. Altitude Acquisition Corp. declined to comment. Getaround did not immediately respond to requests for comment.
お知らせ • May 18Altitude Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 19Aerion Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionAerion Corporation is in talks to go public through a merger with Altitude Acquisition Corp. (NasdaqCM:ALTU), according to people with knowledge of the matter. The companies are discussing a deal that would value the combined firm at up to $3 billion, said the people, who asked to not be identified because the matter isn’t public. A deal could be announced as soon as in February 2021, the people said. The talks could still fall apart and end without an agreement, they said. A spokesperson for Aerion declined to comment. A representative for Altitude Acquisition didn’t immediately respond to a request for comment.